What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Filgotinib with methotrexate demonstrated a statistically significant improvement in primary outcomes (ACR20) compared to both adalimumab and placebo in the FINCH1 trial, with results showing 76.6% versus 70.5% and 49.9% respectively (p<0.05). Additionally, it showed improvements in key secondary endpoints, indicating a clear clinical advantage over existing treatments.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for filgotinib with methotrexate are around £20,000 per QALY gained, which is considered acceptable by NICE. The committee noted that despite uncertainties, the treatment is likely to represent a good use of Healthcare resources for patients with moderate rheumatoid arthritis.
Is there quality-of-life evidence payers weigh? — Quality of life
The mapping algorithm used to derive utility values from HAQ-DI scores was validated and deemed appropriate for decision-making. The committee acknowledged that the benefits of filgotinib were adequately captured in the cost-effectiveness analysis, indicating a moderate improvement in HRQoL.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Filgotinib was reported to have a very good safety profile, with mostly mild or moderate adverse events. The committee noted that the adverse effects were manageable and comparable to existing therapies, indicating a strong tolerability.
Was the drug compared against what payers expect? — Comparator Selection
While the trials included relevant comparators such as adalimumab and placebo, there were no direct comparisons with the full range of biological DMARDs for severe disease. The committee accepted the indirect comparisons but acknowledged limitations in the evidence base.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a representative population of patients with moderate to severe rheumatoid arthritis, with a significant proportion having inadequate responses to previous treatments. The committee concluded that the overall moderate population from the FINCH1 trial was appropriate for decision-making.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Filgotinib can be integrated into existing treatment pathways with minimal adjustments, as it is recommended for patients who have not responded adequately to conventional DMARDs. The oral administration is also favorable for patient compliance.
Are the wider system costs understood? — Resource Use and Cost Implications
The cost implications of filgotinib are manageable, with the potential for net savings due to its effectiveness in treating moderate to severe rheumatoid arthritis. The committee noted that the treatment is likely to be cost-effective within the Healthcare framework.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by two robust RCTs (FINCH1 and FINCH2) with low bias risk. The committee accepted the evidence for decision-making, although some limitations were noted regarding the comparators used.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding the long-term progression rates and treatment sequences, the committee found the overall context supportive of filgotinib’s use, particularly for patients with unmet needs in moderate disease.
